Perthera AI

Perthera AI offers a proprietary Personalized Cancer Therapy service that helps oncologists identify the best treatment options for patients to fight cancer.

Perthera AI has pioneered the use of advanced multi-omic molecular analysis combined with a comprehensive "data lake" of patient specific outcomes and medical history to advise doctors & patients on optimal treatment options through the Oncology Operating System™. Perthera uses AI to identify the best drugs available for that individual, giving patients a 'performance prediction score' for every a

At ASCO '23, AI Precision Oncology Company Perthera Unveils Premium Experience for Clinicians with New Options for Ordering and Access to Enhanced Perthera Analytics 06/02/2023

Excited to be at and wanted to share some news about Perthera AI. If you're in Chicago this weekend, stop by booth #26116 and say hello. We have lots to share!

At ASCO '23, AI Precision Oncology Company Perthera Unveils Premium Experience for Clinicians with New Options for Ordering and Access to Enhanced Perthera Analytics /PRNewswire/ -- ASCO 2023 – McCormick Place, In advance of a new Current Procedural Terminology (CPT) Category III code that will go into effect on July 1st,...

03/03/2023

The Perthera AI Clinical Team is proud to to support the Colorectal Cancer Alliance in its mission to end colorectal cancer.

Did you know that In 2023, an estimated 153,020 people will be diagnosed with this highly preventable disease? They will join more than 1.4 million colorectal cancer patients and survivors living today. We go blue for them, their families, and their community.

02/06/2023

New Category III CPT Code for Precision Oncology Decision Support Platform at Perthera

www.perthera.com

Massive Bio and Perthera.ai Partner to Empower Cancer Patients with Personalized Therapies and Accurate Trial Recommendations 10/05/2022

We are thrilled to announce a strategic partnership with Massive Bio to empower more cancer patients to find an appropriate clinical trial. Read more about how we are offering personalized therapies and accurate trial recommendations: https://www.businesswire.com/news/home/20221005005225/en/Massive-Bio-and-Perthera.ai-Partner-to-Empower-Cancer-Patients-with-Personalized-Therapies-and-Accurate-Trial-Recommendations

Massive Bio and Perthera.ai Partner to Empower Cancer Patients with Personalized Therapies and Accurate Trial Recommendations Massive Bio and Perthera.ai announced a partnership to empower more cancer patients to find an appropriate clinical trial, with the help of AI.

PERTHERA AI ANALYTICS LAUNCHES IMPROVED ANALYTICS, CLINICAL TRIAL OPTIMIZATION AND PATIENT CARE MANAGEMENT TOOL AT ASCO 06/06/2022

is a wrap and we are thrilled to have so many people stop by the booth to learn more about our new AI Analytics platform. Now available to Centers across the country:
https://www.einpresswire.com/article/575591314/perthera-ai-analytics-launches-improved-analytics-clinical-trial-optimization-and-patient-care-management-tool-at-asco

PERTHERA AI ANALYTICS LAUNCHES IMPROVED ANALYTICS, CLINICAL TRIAL OPTIMIZATION AND PATIENT CARE MANAGEMENT TOOL AT ASCO Perthera AI’s proven data mining, analytics, optimization and care management platform now available for cancer centers to utilize for their own data analysis.

Timeline photos 05/26/2022

📍📍📍 Stop by Booth 27102 at the American Society of Clinical Oncology ( ) Annual Meeting in Chicago to experience our new RWE Analytics interface tool that advances data curation and trial selection; hear more about our ground-breaking research and collaborations; and meet the Perthera team, including our new President & CEO, Albert Kelley. Read more here: https://bit.ly/Perthera_ASCO

FDA approves second CAR-T cancer therapy to treat multiple myeloma, opening the door for greater access 03/31/2022

The FDA approved a new CAR-T therapy for multiple myeloma, a move that could ease strain on limited supplies of potentially lifesaving cancer therapies.

FDA approves second CAR-T cancer therapy to treat multiple myeloma, opening the door for greater access The FDA has approved a new CAR-T therapy for multiple myeloma, a move that could ease strain on limited supplies of potentially lifesaving cancer therapies.

Prostate Cancer Diversity in Clinical Trials Helps 03/28/2022

Clinical trials often lack diversity. Here's how to fix that.

Prostate Cancer Diversity in Clinical Trials Helps To develop better prostate cancer treatments and more successful outcomes, more diverse clinical trials are necessary.

03/24/2022

The Association of Community Cancer Centers (ACCC) has launched a set of resources designed to help healthcare facilities and professionals understand and implement precision oncology medicine at their organizations.

https://bit.ly/360qNYZ

bit.ly

Landmark year ahead for colorectal cancer testing and liquid biopsies 03/23/2022

"With pivotal clinical trials for new cancer blood tests – so-called ‘liquid biopsies’ – occurring in 2022, transformative change for the diagnostics surrounding CRC may be around the corner."

Landmark year ahead for colorectal cancer testing and liquid biopsies March is National Colorectal Cancer (CRC) Awareness Month, a time aimed at raising awareness for what is the world’s second leading cause of cancer death worldwide. With pivotal clinical trials for new cancer blood tests – so-called ‘liquid biopsies’ – occurring in 2022, transformative cha...

Infographic: 3 Trends to Track in Health Care 03/17/2022

3 Trends to Track in Health Care



https://bit.ly/3tP8cHa

Infographic: 3 Trends to Track in Health Care Avera is at the forefront of health care trends as we evolve everything from cancer treatments to 24/7 access. Watch these three trends in the coming years.

Researchers develop a system of synthetic biosensors to assess the response of cancer therapy 03/15/2022

Gabe Kwong, Associate Professor at Georgia Tech and Emory University, and his team have developed a system of synthetic biosensors that will let a patient and doctor quickly learn if an ICB therapy is working through a non-invasive urinalysis.



https://bit.ly/36fdV0X

Researchers develop a system of synthetic biosensors to assess the response of cancer therapy Immune checkpoint blockade (ICB) inhibitors have transformed the treatment of cancer and have become the frontline therapy for a broad range of malignancies. It's because they work better than the previous standard of care.

Lung Cancer Screening: Do You Need It? 03/14/2022

Learn from the Cleveland Clinic why lung screenings are important and who can benefit from them: https://cle.clinic/3J2UHKB

Lung Cancer Screening: Do You Need It? Know the benefits and risks

08/01/2021

World Lung Cancer Day is on August 1st and Perthera remains committed with our proven Precision Medicine Oncology Platform to advance physician's and patient's fight against lung cancer.

To find out more please reach out to us at [email protected] or visit our website https://perthera.com

06/28/2021
Data Science: Improving care for patients with cancer - MLSC 03/30/2021

Perthera is pleased to be featured as part of the Massachusetts Life Sciences Center Data Science internship program. Leading the way to improve patient outcomes!

https://www.masslifesciences.com/success-story/data-science-improving-care-for-patients-with-cancer/

Data Science: Improving care for patients with cancer - MLSC Life sciences is an ever-evolving industry that continues to push the landscape in how we treat diseases, develop new modalities, and redefine the careers created within this ecosystem. One such...

Want your business to be the top-listed Engineering Company in McLean?
Click here to claim your Sponsored Listing.

Category

Telephone

Address


8200 Greensboro Drive Suite 350
McLean, VA
22102

Opening Hours

Monday 8:30am - 5:30pm
Tuesday 8:30am - 5:30pm
Wednesday 8:30am - 5:30pm
Thursday 8:30am - 5:30pm
Friday 8:30am - 5:30pm

Other Biotechnology in McLean (show all)
D-Prime LLC D-Prime LLC
6731 Whittier Avenue
McLean, 22101

We create new insights and capabilities to improve health and performance.

Perthera, Inc. Perthera, Inc.
8200 Greensboro Drive
McLean, 22102

Perthera, Inc. is helping extend cancer patients’ lives by utilizing precision medicine and Perthera AI to produce its Perthera Report, giving cancer patients ranked therapy option...